MaaT Pharma Joins Microbiome Therapeutics Innovation Group
20 Luglio 2023 - 6:00PM
Business Wire
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a
clinical-stage biotechnology company and a leader in the
development of Microbiome Ecosystem TherapiesTM (MET) dedicated to
improving survival outcomes for patients with cancer, today
announced that the Company is now a member of Microbiome
Therapeutics Innovation Group (MTIG). MTIG is a coalition of
companies leading the research and development of FDA-approved
microbiome therapeutic drugs and microbiome-based products to
address unmet medical needs, improve clinical outcomes, and reduce
health care costs.
"We are pleased to welcome MaaT Pharma to our diverse coalition
of microbiome-based companies. Microbiome medicines hold great
potential for the treatment of oncology diseases and Hervé
Affagard’s team is dedicated to bringing therapies that improve
survival in cancer,” commented MTIG Chairman & CEO of Siolta
Therapeutics, Nikole Kimes, Ph.D. “We look forward to working
alongside MaaT Pharma’s world-leading scientists as we seek to
implement tangible policy solutions that accelerate the development
and integration of life-saving FDA approved microbiome therapies
into clinical practice.”
MaaT Pharma Chief Executive Officer Hervé Affagard added,
“We are very proud to join the Microbiome Therapeutics Innovation
Group as we share the group’s mission of advancing microbiome-based
therapies to improve clinical outcomes for patients. We eagerly
anticipate a productive and collaborative partnership with MTIG and
its members to accelerate the transformation of fundamental
research into market-ready microbiome innovations.”
The Microbiome Therapeutics Innovation Group (MTIG) is a
coalition of companies leading the research and development of
FDA-approved microbiome therapeutics and microbiome-based products
to address unmet medical needs, improve clinical outcomes, and
reduce health care costs. The human microbiome is one of the new
frontiers of medical innovation that has the potential to benefit
patients suffering from numerous diseases afflicting millions of
patients and consuming billions of dollars of healthcare resources.
MTIG is committed to working with stakeholders who share in our
mission and seek tangible policy and regulatory solutions in the
emerging microbiome arena. Through a collective voice, the MTIG
membership works together to enhance the regulatory, investment,
and commercial environment to accelerate microbiome therapeutic
product development and enable the field to reach its potential to
benefit patients.
Today, MTIG is comprised of twelve microbiome therapeutics
companies: Bacthera, BiomeSense, Bio-Me, Genetic Analysis, MaaT
Pharma, Microba Life Sciences, Rebiotix, Inc., a Ferring Company,
Seres Therapeutics, Servatus Biopharmaceuticals, Siolta
Therapeutics, and Vedanta Biosciences. For more information, visit
www.microbiometig.org.
About MaaT Pharma
MaaT Pharma, a clinical-stage biotechnology company, has
established a complete approach to restoring patient-microbiome
symbiosis in oncology. Committed to treating cancer and
graft-versus-host disease (GvHD), a serious complication of
allogeneic stem cell transplantation, MaaT Pharma has launched, in
March 2022, an open-label, single-arm Phase 3 clinical trial in
patients with acute GvHD, following the achievement of its proof of
concept in a Phase 2 trial. Its powerful discovery and analysis
platform, gutPrint®, enables the identification of novel disease
targets, evaluation of drug candidates, and identification of
biomarkers for microbiome-related conditions. The company’s
Microbiome Ecosystem Therapies are produced through a standardized
cGMP manufacturing and quality control process to safely deliver
the full diversity of the microbiome in liquid and oral
formulations. MaaT Pharma benefits from the commitment of
world-leading scientists and established relationships with
regulators to support the integration of the use of microbiome
therapies in clinical practice. MaaT Pharma is listed on Euronext
Paris (ticker: MAAT).
Forward-looking Statements
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230720303697/en/
MaaT Pharma – Investor Relations Guilhaume Debroas, Ph.D.
Head of Investor Relations +33 6 16 48 92 50
invest@maat-pharma.com
MaaT Pharma – Media Relations Pauline RICHAUD Senior PR
& Corporate Communications Manager +33 6 14 06 45 92
media@maat-pharma.com
Trophic Communications – Corporate Communications
Charlotte SPITZ or Stephanie MAY +49 171 351 2733
maat@trophic.eu
Grafico Azioni Maat Pharma (EU:MAAT)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Maat Pharma (EU:MAAT)
Storico
Da Mag 2023 a Mag 2024